ABT NG DES 48 EECSS
Device
Abbott Laboratories
Total Payments
$246,023
Transactions
137
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $93,467 | 81 | 0 |
| 2020 | $152,556 | 56 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $246,023 | 137 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Abbott Next Generation Drug Eluting Stent 48mm Study (SPIRIT 48) | Abbott Laboratories | $152,556 | 0 |
| A Clinical Investigation to Assess the Abbott Next Generation Drug Eluting Stent 48mm Everolimus Eluting Coronary Stent System (EECSS) in Treatment of de Novo Native Coronary Artery Disease (SPIRIT 48) | Abbott Laboratories | $92,467 | 0 |
| Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal (TRILUMINATE) | Abbott Laboratories | $1,000 | 0 |
Top Doctors Receiving Payments for ABT NG DES 48 EECSS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Missoula, MT | $246,023 | 137 |
Ad
Manufacturing Companies
- Abbott Laboratories $246,023
Product Information
- Type Device
- Total Payments $246,023
- Total Doctors 0
- Transactions 137
About ABT NG DES 48 EECSS
ABT NG DES 48 EECSS is a device associated with $246,023 in payments to 0 healthcare providers, recorded across 137 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2020 to 2023. In 2023, $93,467 was paid across 81 transactions to 0 doctors.
The most common payment nature for ABT NG DES 48 EECSS is "Unspecified" ($246,023, 100.0% of total).
ABT NG DES 48 EECSS is associated with 3 research studies, including "Abbott Next Generation Drug Eluting Stent 48mm Study (SPIRIT 48)" ($152,556).